Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070886 · ClinicalTrials.gov registry record · Phase 2
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
A Phase 2 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 612
- Enrollment target
NCT03070886 is a Phase 2 study that has completed, run by NRG Oncology. The registered enrollment target is 612 participants.
The verdict
NCT03070886, a Phase 2 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 612 participants
- Enrollment target
Study Summary
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.
Interventions
- DRUG Docetaxel
- RADIATION External Beam Radiation Therapy
- DRUG Bicalutamide
- DRUG Degarelix
- DRUG Flutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070886
The ClinicalTrials.gov registry entry for NCT03070886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT03070886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03070886 about?
NCT03070886 is a clinical study titled "Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery". This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prost...
What is the current status of trial NCT03070886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 612 participants. The study started on 2017-04-05. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT03070886?
The interventions under investigation include: Docetaxel (DRUG), External Beam Radiation Therapy (RADIATION), Bicalutamide (DRUG), Degarelix (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT03070886?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.